Blackstone Life Sciences

Blackstone Life Sciences (BXLS) is the dedicated life-sciences investing platform of Blackstone, managing roughly $15 billion in assets as of Q4 2025. In March 2026 it closed Fund VI at a record $6.3 billion, the largest private life-sciences fund ever raised. The team finances late-stage drug and device development across biopharma and medtech. Notable transactions include Anthos Therapeutics (sold to Novartis for $3.1B in 2025), a $400M deal with Teva for duvakitug, and a $2B financing collaboration with Alnylam. Portfolio medicines include LEQVIO, AMVUTTRA, and IMBRUVICA.